Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model

Immunology and Cell Biology

Volumn 86, Issue 6, 2008, Pages 506-514

  Molavi, Ommoleila ^a,b   Ma, Zengshuan ^a   Hamdy, Samar ^a   Lai, Raymond ^a   Lavasanifar, Afsaneh ^a   Samuel, John ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CpG; JSI 124; STAT3; Tumor immunosuppression

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; JSI 124; PROTEIN INHIBITOR; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL INFILTRATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DENDRITIC CELL; DRUG MECHANISM; DRUG POTENTIATION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LYMPH NODE; LYMPHOCYTE SUBPOPULATION; MALE; MELANOMA; MONOTHERAPY; MOUSE; NATURAL KILLER CELL; NONHUMAN; REGULATORY T LYMPHOCYTE; SURVIVAL TIME; TUMOR GROWTH;

ANIMALS; BLOTTING, WESTERN; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-2; KILLER CELLS, NATURAL; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TRITERPENES; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 49649097339     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2008.27     Document Type: Article

References (49)

1. Slingluff CL, Speiser DE. Progress and controversies in developing cancer vaccines. J Transl Med 2005; 3: 18-27.
2. Morse MA, Chui S, Hobeika A, Lyerly HK, Clay T. Recent developments in therapeutic cancer vaccines. Nat Clin Pract Oncol 2005; 2: 108-113.
3. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-915.
4. Chen Q, Wang WC, Evans SS. Tumor microvasculature as a barrier to antitumor immunity. Cancer Immunol Immunother 2003; 52: 670-679.
5. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7: 41-51.
6. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005; 11: 1314-1321.
7. Nefedova Y, Gabrilovich DI. Targeting of Jak/STAT pathway in antigen presenting cells in cancer. Curr Cancer Drug Targets 2007; 7: 71-77.
8. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004; 10: 48-54.
9. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21: 685-711.
10. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004; 4: 941-952.
11. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-274.
12. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003; 63: 1270-1279.
13. Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 2005; 65: 9525-9535.
14. Nefedova Y, Cheng P, Gilkes D, Blaskovich M, Beg AA, Sebti SM et al. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J Immunol 2005; 175: 4338-4346.
15. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-745.
16. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987-995.
17. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005; 23: 275-306.
18. Molenkamp BG, van Leeuwen PA, Meijer S, Sluijter BJ, Wijnands PG, Baars A et al. Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin Cancer Res 2007; 13: 2961-2969.
19. Hellman P, Eriksson H. Early activation markers of human peripheral dendritic cells. Hum Immunol 2007; 68: 324-333.
20. Brocks CP, Pries R, Frenzel H, Ernst M, Schlenke P, Wollenberg B. Functional alteration of myeloid dendritic cells through head and neck cancer. Anticancer Res 2007; 27: 817-824.
21. Carpentier AF. [Cancer immunotherapy with CpG-ODN]. Med Sci (Paris) 2005; 21: 73-77.
22. Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 2004; 6: 88-95.
23. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007; 117: 1184-1194.
24. Molavi O, Ma Z, Mahmud A, Alshamsan A, Samuel J, Lai R et al. Polymeric micelles for the solubilization and delivery of STAT3 inhibitor cucurbitacins in solid tumors. Int J Pharm 2008; 347: 118-127.
25. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999; 5: 1249-1255.
26. Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol 2006; 6: 476-483.
27. Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H et al. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 2003; 63: 4095-4100.
28. Wigginton JM, Park JW, Gruys ME, Young HA, Jorcyk CL, Back TC et al. Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis. J Immunol 2001; 166: 1156-1168.
29. Nelson D, Ganss R. Tumor growth or regression: powered by inflammation. J Leukoc Biol 2006; 80: 685-690.
30. Crittenden MR, Thanarajasingam U, Vile RG, Gough MJ. Intratumoral immunotherapy: using the tumour against itself. Immunology 2005; 114: 11-22.
31. Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 2001; 23: 263-272.
32. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92: 4150-4166.
33. Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 1998; 160: 1224-1232.
34. Powrie F, Carlino J, Leach MW, Mauze S, Coffman RL. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J Exp Med 1996; 183: 2669-2674.
35. Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 2005; 201: 1061-1067.
36. Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004; 173: 1444-1453.
37. Wang RF. Immune suppression by tumor-specific CD4+ regulatory T-cells in cancer. Semin Cancer Biol 2006; 16: 73-79.
38. Mimura K, Kono K, Takahashi A, Kawaguchi Y, Fujii H. Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol Immunother 2007; 56: 761-770.
39. Johnson BF, Clay TM, Hobeika AC, Lyerly HK, Morse MA. Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin Biol Ther 2007; 7: 449-460.
40. Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res 2006; 12: 6808-6816.
41. Sharma S, Karakousis CP, Takita H, Shin K, Brooks SP. Intra-tumoral injection of CpG results in the inhibition of tumor growth in murine Colon-26 and B-16 tumors. Biotechnol Lett 2003; 25: 149-153.
42. Chen Z, Han ZC. STAT3: A critical transcription activator in angiogenesis. Med Res Rev 2008; 28: 185-200.
43. Burdelya L, Kujawski M, Niu G, Zhong B, Wang T, Zhang S et al. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol 2005; 174: 3925-3931.
44. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004; 305: 200-205.
45. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998; 58: 3491-3494.
46. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl JMed 2003; 348: 203-213.
47. Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large earlystage cervical cancer. Cancer Res 2007; 67: 354-361.
48. Vicari AP, Chiodoni C, Vaure C, Ait-Yahia S, Dercamp C, Matsos F et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 2002; 196: 541-549.
49. Hui D, Satkunam N, Al Kaptan M, Reiman T, Lai R. Pathway-specific apoptotic gene expression profiling in chronic lymphocytic leukemia and follicular lymphoma. Mod Pathol 2006; 19: 1192-1202.